GHRH (1–44) vs Tesamorelin
Both GHRH (1–44) and Tesamorelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
GHRH (1–44)
Evidence AGrowth Hormone Releasing Hormone, full sequence
The full 44-amino-acid GHRH sequence. The natural pituitary stimulus for GH release. Largely supplanted in clinical use by sermorelin/tesamorelin but remains a research and diagnostic tool.
View full GHRH (1–44) profile →Tesamorelin
Evidence ATesamorelin (Egrifta)
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
View full Tesamorelin profile →Side-by-Side
| Attribute | GHRH (1–44) | Tesamorelin |
|---|---|---|
| Evidence Grade | A | A |
| FDA Status | FDA-approved (Geref) historically as diagnostic GH stimulant; current US availability limited | FDA-approved for HIV-associated lipodystrophy |
| Typical Dose | 1 mcg/kg IV (diagnostic test) | 2 mg daily (subcutaneous) |
| Clinics Indexed | 22 | 178 |
| Categories | growth-hormone | growth-hormone, fat-loss |
Key reported benefits — GHRH (1–44)
- ✓Endogenous GH stimulation
- ✓Diagnostic GH testing
Key reported benefits — Tesamorelin
- ✓Visceral fat reduction
- ✓Natural GH stimulation
- ✓Cognitive benefit
- ✓Lean mass
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.